News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
679,146 Results
Type
Article (41469)
Company Profile (620)
Press Release (637057)
Section
Business (208789)
Career Advice (2578)
Deals (36858)
Drug Delivery (88)
Drug Development (81081)
Employer Resources (172)
FDA (15859)
Job Trends (15512)
News (350608)
Policy (31879)
Tag
Academia (1992)
Africa (831)
Alabama (32)
Allergies (40)
Alliances (51049)
Alzheimer's disease (1114)
Antibody-drug conjugate (ADC) (55)
Approvals (15806)
Arizona (114)
Artificial intelligence (55)
Asia (41237)
Australia (6785)
Bankruptcy (369)
Best Places to Work (11188)
Biosimilars (54)
C2C Services and Suppliers (78002)
California (829)
Canada (641)
Cancer (183)
Career advice (2164)
CAR-T (36)
Cell therapy (72)
China (50)
Clinical research (63076)
Collaboration (58)
Colorado (35)
COVID-19 (2405)
Cystic fibrosis (68)
Diabetes (33)
Diagnostics (6080)
Diversity, equity & inclusion (41)
Drug pricing (55)
Earnings (83683)
Employer resources (145)
Europe (91007)
Events (110846)
FDA (15900)
Florida (95)
Funding (40)
Gene therapy (54)
GLP-1 (517)
Government (3590)
Healthcare (17701)
Hotbed/Location (470243)
Idaho (56)
Illinois (185)
Indiana (106)
Infectious disease (2418)
Inflammatory bowel disease (89)
Interviews (501)
IPO (16896)
Job creations (4431)
Job search strategy (1820)
Kansas (87)
Layoffs (436)
Legal (8014)
Liver cancer (52)
Lung cancer (40)
Maine (50)
Management (56)
Manufacturing (54)
Maryland (211)
Massachusetts (460)
Medical device (13460)
Medtech (13463)
Mergers & acquisitions (19641)
Metabolic disorders (166)
Neuroscience (1200)
New Jersey (63)
New York (81)
NextGen Class of 2024 (6596)
Non-profit (3479)
North Carolina (172)
Obesity (105)
Opinion (216)
Parkinson's disease (30)
Patents (37)
Peanut (36)
Pennsylvania (51)
People (57729)
Phase I (19538)
Phase II (27910)
Phase III (21040)
Podcasts (45)
Policy (38)
Postmarket research (2406)
Preclinical (8191)
Rare diseases (88)
Real estate (6114)
Recruiting (68)
Regulatory (20981)
Research institute (1923)
Resumes & cover letters (399)
South America (1219)
Startups (3922)
Texas (87)
United States (2937)
Vaccines (442)
Washington State (116)
Weight loss (106)
Date
Today (44)
Last 7 days (494)
Last 30 days (1941)
Last 365 days (39840)
2024 (22653)
2023 (41259)
2022 (51890)
2021 (55813)
2020 (53702)
2019 (46002)
2018 (35012)
2017 (33989)
2016 (32989)
2015 (38606)
2014 (32106)
2013 (27545)
2012 (28799)
2011 (28778)
2010 (26885)
679,146 Results for "merck and company".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Infectious Disease
CDC Backs Merck’s Capvaxive, Tees Up Pneumococcal Competition With Pfizer
In a potential challenge to Pfizer’s Prevnar 20, Merck’s Capvaxive has been recommended by the Centers for Disease Control and Protection for use in preventing invasive pneumococcal disease in adults.
July 1, 2024
·
2 min read
·
Tristan Manalac
Policy
CDC Backs Merck’s Capvaxive, Tees Up Pneumococcal Competition With Pfizer
In a potential challenge to Pfizer’s Prevnar 20, Merck’s Capvaxive has been recommended by the Centers for Disease Control and Protection for use in preventing invasive pneumococcal disease in adults.
July 1, 2024
·
2 min read
·
Tristan Manalac
Deals
Merck to Acquire EyeBio
Merck, known as MSD outside of the United States and Canada, and Eyebiotech Limited, a privately held ophthalmology-focused biotechnology company, announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire EyeBio.
May 29, 2024
·
9 min read
RSV
Merck Challenges AstraZeneca, Sanofi With Phase IIb/III Data for RSV Antibody
Merck’s clesrovimab lowered the risk of medically attended lower respiratory infections associated with RSV infection when used in infants, according to topline results announced Tuesday.
July 23, 2024
·
2 min read
·
Tristan Manalac
Policy
FDA Action Alert: Merck, BMS, Sarepta and More
The FDA has a packed calendar this week, with six decisions on the docket, including ones for Merck’s Keytruda, BMS’s Krazati and Sarepta’s Elevidys.
June 12, 2024
·
4 min read
·
Tristan Manalac
Policy
Merck’s ADC Pact With Daiichi Hits Regulatory Setback in FDA Rejection
The FDA on Thursday rejected Merck and Daiichi Sankyo’s HER3-targeted antibody-drug conjugate patritumab deruxtecan in a Complete Response Letter, citing problems with a third-party manufacturer.
June 27, 2024
·
2 min read
·
Tristan Manalac
Business
Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Merck and Orion Corporation (“Orion”) today announced that notice has been provided of the mutual exercise of an option to convert the companies’ ongoing co-development and co-commercialization agreement for opevesostat (MK-5684/ODM-208), an investigational CYP11A1 inhibitor, and other candidates targeting CYP11A1 into an exclusive global license for Merck.
July 1, 2024
·
8 min read
FDA
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma.
June 17, 2024
·
79 min read
N-Power Medicine Collaborates with Merck to Expand Oncologist and Patient Access to Clinical Trials
N-Power Medicine, a company reinventing the clinical trial process, is collaborating with Merck, known as MSD outside the United States and Canada, to enable a greater number of oncologists, and the patients they care for, to participate in clinical research.
July 1, 2024
·
2 min read
Business
Merck Announces Third-Quarter 2024 Dividend
Merck, known as MSD outside of the United States and Canada, announced that the Board of Directors has declared a quarterly dividend of $0.77 per share of the company’s common stock for the third quarter of 2024.
May 28, 2024
·
3 min read
1 of 67,915
Next